Identification of Adverse Plaque Characteristics by Coronary MR Angiography
Status: | Recruiting |
---|---|
Conditions: | Peripheral Vascular Disease, Cardiology |
Therapuetic Areas: | Cardiology / Vascular Diseases |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/21/2016 |
Start Date: | April 2012 |
End Date: | December 2018 |
Contact: | Daniel S Berman, MD |
Email: | bermand@cshs.org |
Phone: | 310 423-4223 |
Identification of Adverse Plaque Characteristics by Coronary Magnetic Resonance Angiography
This is a pilot study to determine whether coronary magnetic resonance angiography(CMRA)can
identify adverse plaque characteristics (buildup of fat, cholesterol, calcium, and other
substances found in the blood) seen on coronary computed tomography angiography(CCTA) and
evaluate whether there is a relationship between the adverse plaque characteristics and the
presence of coronary artery wall inflammation.
identify adverse plaque characteristics (buildup of fat, cholesterol, calcium, and other
substances found in the blood) seen on coronary computed tomography angiography(CCTA) and
evaluate whether there is a relationship between the adverse plaque characteristics and the
presence of coronary artery wall inflammation.
This pilot study will examine 20 stable patients who have undergone a clinically-indicated
coronary computed tomography angiography (CCTA) for suspected Coronary Artery Disease. They
will be invited to undergo a research coronary Magnetic Resonance Imaging scan with
contrast(CMRA). Based upon the subject's heart rate, a beta blocker may be administered as
its use has been shown to be effective in producing better images as it widens the arteries.
Researchers will use newly developed non-invasive coronary MRA techniques to compare
information shown on the research CMRA with the clinical CCTA. While CCTA has been
demonstrated to be able to provide data on adverse plaque characteristics (APC's), the
ability of CMRA to evaluate these features is not established.
coronary computed tomography angiography (CCTA) for suspected Coronary Artery Disease. They
will be invited to undergo a research coronary Magnetic Resonance Imaging scan with
contrast(CMRA). Based upon the subject's heart rate, a beta blocker may be administered as
its use has been shown to be effective in producing better images as it widens the arteries.
Researchers will use newly developed non-invasive coronary MRA techniques to compare
information shown on the research CMRA with the clinical CCTA. While CCTA has been
demonstrated to be able to provide data on adverse plaque characteristics (APC's), the
ability of CMRA to evaluate these features is not established.
Inclusion Criteria:
- Age ≥18 years
- Ability to comprehend and sign informed consent
- Presence of a non-calcified or mixed plaque without high-grade stenosis in the left
main or a proximal coronary artery segment AND at least one APC present in this
plaque by CCTA (defined as LAP with <30 Hounsfield units or PR with ≥10% increase in
the maximal vessel diameter within the plaque as compared to a proximal reference
segment as previously described10).
Exclusion Criteria:
- High-grade stenosis (≥50% stenosis of the left main artery or ≥70% stenosis of
another proximal coronary segment);
- Coronary artery stent in the segment with the reference plaque
- Possible pregnancy
- Glomerular filtration rate <45 ml/min
- More than 90 days between CCTA and CMRA study
- Any significant arrhythmia (e.g. atrial fibrillation, frequent ectopy)
- Significant asthma
- History of 2nd or 3rd degree heart block
- Allergy or known intolerance to beta-blockers
- Use of phosphodiesterase inhibitor (e.g. Viagra) within the last 48 hours
- Rapid heart rate (heart rate ≥90 beats/minute)
- Severe aortic stenosis (Aortic valve area <1.0 cm2 or mean gradient >30 mmHg)
- Systolic blood pressure <100 mmHg
- Other contraindication to MRI, including metallic implants (valve replacement,
pacemaker, implantable cardiac defibrillator, metallic spine material), intracranial
clips, metallic fragments in eyes, and claustrophobia
We found this trial at
1
site
8700 Beverly Blvd # 8211
Los Angeles, California 90048
Los Angeles, California 90048
(1-800-233-2771)
Principal Investigator: Daniel S Berman, MD
Phone: 310-423-4223
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
Click here to add this to my saved trials